Back to Search Start Over

Clinical value of sequential circulating tumor DNA analysis using next-generation sequencing and epigenetic modifications for guiding thermal ablation for colorectal cancer metastases: a prospective study.

Authors :
Boeken T
Pellerin O
Bourreau C
Palle J
Gallois C
Zaanan A
Taieb J
Lahlou W
Di Gaeta A
Al Ahmar M
Guerra X
Dean C
Laurent Puig P
Sapoval M
Pereira H
Blons H
Source :
La Radiologia medica [Radiol Med] 2024 Oct; Vol. 129 (10), pp. 1530-1542. Date of Electronic Publication: 2024 Aug 25.
Publication Year :
2024

Abstract

Introduction: While thermal ablation is now a standard treatment option for oligometastatic colorectal cancer patients, selecting those who will benefit most from locoregional therapies remains challenging. This proof-of-concept study is the first to assess the feasibility of routine testing of ctDNA before and after thermal ablation with curative intent, analyzed by next-generation sequencing (NGS) and methylation specific digital droplet PCR (ddPCR). Our prospective study primary objective was to assess the prognostic value of ctDNA before thermal ablation.<br />Methods: This single-center prospective study from November 2021 to June 2022 included colorectal cancer patients referred for curative-intent thermal ablation. Cell-free DNA was tested at different time points by next-generation sequencing and detection of WIF1 and NPY genes hypermethylation using ddPCR. The ctDNA was considered positive if either a tumor mutation or hypermethylation was detected; recurrence-free survival was used as the primary endpoint.<br />Results: The study enrolled 15 patients, and a total of 60 samples were analyzed. The median follow-up after ablation was 316 days, and median recurrence-free survival was 250 days. CtDNA was positive for 33% of the samples collected during the first 24 h. The hazard ratio for progression according to the presence of baseline circulating tumor DNA was estimated at 0.14 (CI 95%: 0.03-0.65, pā€‰=ā€‰0.019). The dynamics are provided, and patients with no recurrence were all negative at H24 for ctDNA.<br />Discussion: This study shows the feasibility of routine testing of ctDNA before and after thermal ablation with curative intent. We report that circulating tumor DNA is detectable in patients with low tumor burden using 2 techniques. This study emphasizes the potential of ctDNA for discerning patients who are likely to benefit from thermal ablation from those who may not, which could shape future referrals. The dynamics of ctDNA before and after ablation shed light on the need for further research and larger studies.<br /> (© 2024. Italian Society of Medical Radiology.)

Details

Language :
English
ISSN :
1826-6983
Volume :
129
Issue :
10
Database :
MEDLINE
Journal :
La Radiologia medica
Publication Type :
Academic Journal
Accession number :
39183242
Full Text :
https://doi.org/10.1007/s11547-024-01865-0